Blog

Sep 7, 2024, 11:19

Meet the speakers of CityU – AFCR Symposium – Leslie Leinwand

CityU-AFCR Symposium on Precision Medicine and Digital Medicine will go on from 12-13 September as part of BIOHK2024.

The symposium will showcase presentations by BRACE award winners and experts in precision medicine, providing a dynamic platform for the exchange of innovative ideas and fostering a collaborative environment for advancements in the biotechnology field.

Symposium

One of the Speakers is Leslie Leinwand

Leslie Leinwand, PhD is a Molecular, Cellular, and Developmental Biology (MCDB) Distinguished Professor and the Chief Scientific Officer of the BioFrontiers Institute at the University of Colorado Boulder. She was recruited to be Chair of MCDB in 1995. She received her Bachelor’s degree from Cornell University, her PhD from Yale University and did post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado in 1995. She co-founded Myogen, Inc. which was sold to Gilead Pharmaceuticals.

She was also a co-founder of Hiberna, Inc, and more recently of MyoKardia, Inc, a publicly traded company founded to develop therapeutics for inherited cardiomyopathies. She is a Fellow of the AAAS, former MERIT Awardee of the NIH, Established Investigator of the American Heart Association and was recently elected to the American Academy of Arts and Sciences and the National Academy of Inventors.

The interests of Dr. Leinwand’s laboratory are the genetics and molecular physiology of inherited diseases of the heart and how gender and diet modify the heart. The study of these diseases has required multidisciplinary approaches, involving molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of human tissues. Her teaching was recognized by funding from the Howard Hughes Medical Institute’s Professor Program.

During CityU – AFCR Symposium Leslie Leinwand will speak about a topic named ‘From Bench to Bedside: The Role of Basic Science in Treating a Deadly Heart Disease ‘ on September 12.

For more information about CityU-AFCR Symposium visit oncodaily.com